How Eli Lilly’s New GLP-1 Pill Foundayo Stacks Up Against Wegovy and Other Weight-Loss Drugs

This week, the U.S. Food and Drug Administration (FDA) has granted approval for a second GLP-1 medication in an oral form specifically for weight management. The newly approved drug, named Foundayo and developed by Eli Lilly, has shown promising results in clinical trials. Studies revealed that participants using Foundayo experienced an average weight loss of 27 pounds over a 72-week treatment period, offering a new oral option for individuals seeking effective pharmacological interventions for obesity.